MGC Pharma has released an app for both medical patients and professionals alike, to keep track of their CannEpil treatments as well as the latest studies on cannabinoid medicines.
MGC Pharmaceuticals Ltd (ASX: MXC), a European based biopharma company specializing in the production and development of phytocannabinoid-derived medicines, today revealed that the company has launched the CannEpil App, which is available on the Apple App Store as well as the Google Play Store.
The app is designed for patients, and their guardians, who are taking MGC's novel cannabinoid formula CannEpil, which is designed to treat drug-resistant forms of epilepsy.
In addition to providing information for patients, the CannEpil App will also help medical professionals by providing them access to the International Library of Cannabinoids (ILC) as part of its collaboration with the Royal Melbourne Institute of Technology (RMIT).
The App will record patient responses to medical questionnaires as part of their treatment plan and the treating practitioner will be able to view the responses in real-time. MGC Pharma will also have access to the data on a fully anonymized basis to evaluate and report the efficacy of CannEpil®.
The International Library of Cannabinoids (ILC) The ILC is a world-first centralized platform compiling the diverse range of existing data on the therapeutic benefits of cannabinoids. The ILC database has been designed to collect comprehensive information about clinical trials, including details of diseases and follow-up treatments, as well as product identifiers, including genetics, grow conditions, and chemical profile to provide doctors with an encyclopedia of exhaustive information on the best treatment for patients using cannabinoids.
The ILC has also been recognized in a paper titled Automated Gathering and Analysis of Cannabinoids Treatment Data, published in the Journal of Procedia Computer Science, which outlines the strategic benefits of the ILC platform. The launch of the CannEpil® App as part of the development of the ILC is a strategic milestone in the Company's progress as it strengthens its medicinal cannabis IP and allows MXC to remain at the forefront of cannabinoid development with its data.
Data collection on this scale also represents a major step forward for the industry by providing transparent and comprehensive information on specific treatments, therapeutic benefits, wider implications and to advance and enhance the suites of products that are currently available to patients.
This is crucial, as we've discussed previously here at The Green Fund, as one of the biggest barriers identified when it comes to cannabinoid medicines is a lack of knowledge on the part of medical professionals.
Data is extremely important in the healthcare industry and is something that is not widely collected or stored at this time within the medicinal cannabis sector Roby Zomer, Co-founder and Managing Director of MGC Pharma
Roby Zomer, the Co-Founder and Managing Director of MGC Pharma went on to say that:
"The App and the ILC provides the medical community with access to what doctors need the most in order to start adopting and implementing phytocannabinoid treatments into their treatment toolkit: validated patient-based data, collected according to globally recognized standards, available for efficient comparative medical decision making and prescription."
"The use of the data we collect in this way is designed to aid the Phytocannabinoid industry as a whole and to fill the void where there has been a significant lack of knowledge and data, responsibly collected and maintained. MXC believes this data will be invaluable for future product development, health and safety studies, and much more."
Associate Professor Nitin Mantri, RMIT University, who co-designed CannEpil® App and ILC, commented:
"In this age of digital health and precision medicine, collecting patient data real-time allows the doctors to monitor treatment and titer dosing as required. It also benefits the industry to understand the various outcomes expected from the medicine and use this knowledge to further develop the products."
"Whilst the CannEpil® app focuses on patient outcomes for a specific formulation, ILC collects data for all different types of cannabis strains and their efficacy for treating various disorders. ILC when used by leading cannabis researchers and industries will gather evidence to demonstrate policymakers and community the various benefits of the cannabis plant."
Dr. Nadya Lisovoder, Clinical Research Officer for MGC Pharma, commented:
"The medical community around the world is expecting scientific based data concerning the safety and efficacy of medical cannabis-based treatments. In parallel with randomized clinical trials, which MGC Pharma is ahead of the curve in several indications, this active collection of medical data will support the personalization of treatments, facilitate the R&D process and encourage dialog with the medical community, which is crucial to developing viable products for the market."
"This data will be comprised of the demographic profile of the patients, concomitant treatments, and adverse events. The efficacy data will be evaluated with tools that are validated by regulatory agencies and medical communities. We believe that this will allow MGC Pharma to base future developments on a deeper understanding of the treatments being developed, and create better products for more patients, globally."
To learn more about MGC Pharma, visit the company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors